Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.43 |
| ▸ | WNT3A | P56704 | 2/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | QPCT | Q16769 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25763033 | 0.94 | KCNH2 (0.48) | KCNH2ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL30236532 | 0.88 | ALDH1A1 (0.44) | KCNH2ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL257337 | 0.88 | ALDH1A1 (0.44) | KCNH2ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL22681770 | 0.85 | KCNH2 (0.48) | KCNH2ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL29941381 | 0.84 | ALDH1A1 (0.50) | KCNH2ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL172501 | 0.84 | ALDH1A1 (0.50) | KCNH2ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL22681574 | 0.81 | KCNH2 (0.43) | KCNH2GAACTNNB1WNT3A | |
| SCHEMBL22681824 | 0.80 | KCNH2 (0.50) | KCNH2CTNNB1WNT3AHTR1DHTR2C | |
| SCHEMBL11926939 | 0.78 | ALDH1A1 (0.49) | KCNH2ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL12526764 | 0.78 | KCNH2 (0.38) | KCNH2CTNNB1WNT3AHTR1DHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | BASF SE (DE) | 2019-03-05 | — | — | US | claimed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | claimed |
| US-7169775-B2 | Amino methyl imidazoles as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-01-30 | — | — | US | claimed |
| CN-1646497-A | Novel arylimidazoles and related compounds as modulators of the C5a receptor | NEUROGEN CORP (US) | 2005-07-27 | — | — | CN | claimed |
| EP-1490343-A1 | NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS | Neurogen Corporation (US) | 2004-12-29 | — | — | EP | claimed |
| US-20040116424-A1 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION | 2004-06-17 | — | — | US | claimed |
| US-20040082577-A1 | Amino methyl imidazoles as C5a receptor modulators | NEUROGEN CORPORATION | 2004-04-29 | — | — | US | claimed |
| WO-2004018460-A1 | AMINO METHYL IMIDAZOLES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-03-04 | — | — | WO | claimed |
| WO-2003082829-A1 | NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2003-10-09 | — | — | WO | claimed |
| US-20230373934-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA INC. (CA) | 2023-11-23 | — | — | US | disclosed |
| EP-3183250-B1 | PROCESS FOR PREPARING CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL | CLAP CO LTD (KR) | 2023-10-04 | — | — | EP | disclosed |
| EP-4227307-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | Genzyme Corporation (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023114954-A1 | PYRAZOLOPYRAZINE COMPOUNDS AS SHP2 INHIBITORS | GENZYME CORPORATION (US) | 2023-06-22 | — | — | WO | disclosed |
| EP-3582783-B1 | 7-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | TREVENA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20040116424-A1 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION | 2004-06-17 | — | — | US | disclosed |
| US-20040082577-A1 | Amino methyl imidazoles as C5a receptor modulators | NEUROGEN CORPORATION | 2004-04-29 | — | — | US | disclosed |
| WO-2004018460-A1 | AMINO METHYL IMIDAZOLES AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| US-20040014782-A1 | Combination therapy for the treatment of diseases involving inflammatory components | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2004-01-22 | — | — | US | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |
| WO-2003082829-A1 | NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082577-A1 | Amino methyl imidazoles as C5a receptor modulators | C5AR1, C5AR2, C3AR1 | KCNH2 1404/4885ALDH1A1 3627/4885GAA 4885/4885 |
| US-20040014782-A1 | Combination therapy for the treatment of diseases involving inflammatory components | C5AR1, C5AR2, C3AR1 | KCNH2 3554/4885ALDH1A1 2679/4885GAA 3404/4885 |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | STOM, SPOP, TTR | KCNH2 1623/4885ALDH1A1 4757/4885GAA 2162/4885 |
| US-20230373934-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, SHBG, NR5A1 | KCNH2 3272/4885ALDH1A1 809/4885GAA 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.